Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Talquetamab/Teclistamab May Address Need for Improved Survival Outcomes in R/R Myeloma With Extramedullary Disease

August 25th 2025

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Dr Sidana on the Efficacy of Second-Line Cilta-Cel in Relapsed/Refractory Myeloma

August 21st 2025

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

Clinical Perspectives: Analyzing Real-World Data With Bispecifics in R/R MM

August 21st 2025

Panelists discuss how real-world bispecific data shows slight efficacy drops compared with clinical trials but still demonstrates effectiveness in patients who wouldn't meet trial criteria, particularly for bridging to chimeric antigen receptor (CAR) T-cell therapy

Strategic Use of BCMA- and GPRC5D-Directed Bispecifics in R/R MM

August 21st 2025

Panelists discuss how bispecific antibodies are integrated into relapsed/refractory myeloma treatment, with GPRC5D-targeted agents preferred for bridging to chimeric antigen receptor (CAR) T-cell therapy and B-cell maturation antigen (BCMA)-targeted agents for non-CAR T candidates.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

FDA Issues CRL for SC Daratumumab Plus VRd for Transplant-Ineligible or -Deferred, Newly Diagnosed Multiple Myeloma

August 19th 2025

The FDA issued a complete response letter for subcutaneous daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

Trispecific Antibody JNJ-5322 Shows Potential to Redefine Treatment in R/R Multiple Myeloma

August 18th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the rationale for evaluating the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Mewawalla on Unmet Needs After Early CAR T-Cell Therapy in Relapsed/Refractory Myeloma

August 18th 2025

Prerna Mewawalla, MD, discusses needs that remain to be addressed in patients with relapsed/refractory myeloma who receive earlier-line CAR T-cell therapy.

Dr Raza on Talquetamab Plus Teclistamab in R/R Myeloma and Extramedullary Disease

August 15th 2025

Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Novel Lipo-MIT–Based Triplet Drives Responses in R/R Myeloma

August 15th 2025

Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma

BCMA-Targeted Therapy Sequencing: Where Will Belantamab Fit in the Current R/R MM Treatment Landscape?

August 14th 2025

s discuss how belantamab mafodotin should be sequenced with chimeric antigen receptor (CAR) T-cell therapy, noting that prior B-cell maturation antigen (BCMA)-directed therapies can reduce CAR T efficacy and recommending CAR T first when patients are candidates.

What’s Next in CAR T? Emerging Therapies Potentially Reshaping R/R MM

August 14th 2025

Panelists discuss how emerging chimeric antigen receptor (CAR) T-cell therapies such as anito-cel show promise with potentially reduced neurologic toxicity while maintaining efficacy, and dual-targeting approaches such as CD19-B-cell maturation antigen (BCMA) constructs may provide better long-term remissions by targeting potential myeloma stem cell populations.

Daratumumab Delays Clinical Progression, Provides Proof-of-Concept for Early Intervention in MRD-Relapsed Multiple Myeloma

August 12th 2025

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 8/3

August 10th 2025

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

SAR446523 Receives FDA Orphan Drug Designation for R/R Myeloma

August 9th 2025

The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.

Coordinating Post CAR T Care in MM: Bridging Academic and Community Practice

August 7th 2025

Panelists discuss how post-chimeric antigen receptor (CAR) T follow-up care involves coordinated joint visits between academic centers and community oncologists for the first 3 months, with ongoing education about delayed toxicities such as cranial nerve palsies, parkinsonism, and immune effector cell enterocolitis

Early Referral and Patient Education: Setting the Stage for CAR T in MM

August 7th 2025

Panelists discuss how early referral for chimeric antigen receptor (CAR) T-cell therapy is crucial for accessing clinical trials and achieving optimal outcomes, with comprehensive patient education covering unique adverse effects such as cytokine release syndrome (CRS), neurologic toxicities, and secondary malignancies balanced against extraordinary efficacy data.

Questions Arise As CAR T-Cell Therapy and Bispecific Antibody Use Increase in Relapsed/Refractory Myeloma

August 6th 2025

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.